Astrana Health, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report; the supplied text does not provide a clear standalone fourth-quarter financial result. The company, formerly Apollo Medical Holdings, Inc., adopted the Astrana Health name and ASTH ticker in February 2024.
Business context
Astrana is a provider-centric, technology-enabled healthcare company that coordinates and delivers value-based care, primarily in California, Nevada, and Texas. Its three reportable segments are Care Partners, Care Delivery, and Care Enablement. At year-end, it coordinated care for approximately 0.9 million patients through more than 10,000 contracted physicians and managed 15 affiliated physician groups.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Total revenue | $1,386.7 million | $1,144.2 million | +21% |
| Operating income | $84.6 million | $104.3 million | −19% |
| Net income | $57.8 million | $45.7 million | +26% |
| Net income attributable to Astrana | $60.7 million | $45.2 million | +34% |
| Diluted EPS | $1.29 | $0.99 | +$0.30 |
| Operating cash flow | $68.2 million | $82.1 million | −17% |
| Adjusted EBITDA | $146.6 million | $140.0 million | +5% |
| Adjusted EBITDA margin | 11% | 12% | −1 percentage point |
Capitation revenue rose 31% to $1,215.6 million, while risk-pool settlements and incentives fell 46% to $63.5 million. Cost of services increased 24% to $1,171.7 million and general and administrative expense increased 45% to $112.6 million. Operating margin declined to approximately 6.1% from 9.1%; management cited higher medical costs, growth-related spending, personnel costs, acquisition and tax-restructuring expenses, and stock-repurchase excise tax. Higher interest income and a lower income-tax provision contributed to higher net income attributable to Astrana, despite lower operating income.
Cash, cash equivalents, and marketable securities totaled $296.3 million at year-end; working capital was $242.8 million, down from $279.5 million. Total debt was $282.0 million, including a $280.0 million term loan; the company reported no revolver borrowings at year-end. The term loan carried a 7.69% rate, and the average effective rate on total debt was 6.19%. The credit facility provides a $400 million revolver and up to $300 million in term loans. After year-end, the company drew an additional $20 million on the term loan and $90 million on the revolver. Management said liquidity should be sufficient for at least the next 12 months.
Material changes and notable items
- Membership under management fell from approximately 1.3 million to 0.9 million, primarily after an IPA ended its management services agreement; this was partly offset by new physician groups.
- Revenue growth was led by ACO membership in a value-based Medicare model and the May 2023 acquisition of FYB, a restricted Knox-Keene licensed health plan that assumes professional and institutional risk.
- Care Partners revenue rose 24% and operating income rose 8%. Care Delivery revenue rose 25%, but operating income fell 35% as new locations added costs. Care Enablement revenue rose 13%, while operating income fell 29% on higher personnel costs.
- The company expanded its credit facility and used borrowings to repurchase approximately $100 million of shares from APC in November. APC distributed its real-estate investments in a December spin-off; those assets are no longer consolidated after December 26, 2023.
- FY2023 investing cash outflow was $65.5 million, including $28.5 million of property and equipment purchases and $26.5 million of loan issuances. Financing cash flow was $3.4 million, after $284.5 million of borrowings and $204.7 million of debt repayments.
- The four largest payers represented 61.7% of revenue, up from 59.0% in 2022. Medicare revenue increased to $901.3 million from $633.5 million; Medicaid revenue declined to $266.1 million from $280.1 million.
Outlook, risks, and contingencies
For 2024, management guided to revenue of $1.65–$1.85 billion, net income attributable to Astrana of $61–$73 million, Adjusted EBITDA of $165–$185 million, and diluted EPS of $1.28–$1.52. These are forward-looking estimates, not guarantees. The company began participating in the MSSP ENHANCED risk track in 2024 alongside ACO REACH; both programs expose it to potential shared losses and depend on CMS benchmarks, reconciliations, quality results, and beneficiary alignment. The filing also describes the possibility of losses under capitation or global-risk arrangements if medical costs exceed payments.
Key risks include payer concentration; medical-cost and IBNR estimation; changes to Medicare, Medicaid, and value-based-care programs; regulatory limits on corporate practice of medicine and risk-bearing arrangements; and dependence on contractual structures used to consolidate physician-group VIEs. The company also cites California concentration, acquisition and integration execution, cybersecurity and privacy, and access to capital. Its $545 million intercompany loan to Astrana Medical carries a 10% rate, but repayment depends in part on APC preferred dividends; the company’s lenders have security interests in substantially all relevant assets. The company was under IRS examination for 2019–2021 tax returns.
Management reported that the previously identified income-tax control material weakness was remediated by year-end 2023. Management and Ernst & Young reported effective internal control over financial reporting at December 31, 2023, and the auditor issued unqualified opinions on the financial statements and internal controls. The audit identified risk-pool settlements and the $106.7 million medical-liability reserve, including IBNR claims, as critical audit matters. Management said ordinary-course legal matters were not expected to have a material adverse effect, while noting litigation outcomes remain uncertain.
Investor verification priorities
- Reconcile the 2024 guidance, especially the difference between the stated net income attributable to Astrana range and the separate net-income figures in the Adjusted EBITDA reconciliation.
- Track membership after the reported decline, including the impact of the terminated IPA relationship and 2024 acquisitions and partnerships.
- Assess medical-cost trends, IBNR reserve development, risk-pool settlements, and exposure under ACO REACH, MSSP, and global-capitation contracts.
- Review debt covenant headroom, post-year-end borrowing, interest-rate sensitivity, and the repayment prospects for the $545 million intercompany loan.
- Monitor payer concentration, the IRS examination, related-party transactions, and compliance with healthcare licensing and corporate-practice rules.